Target intelligence / Profile preview

Casein kinase 1 alpha 1 like (CSNK1A1L)

Target
CSNK1A1L
Molecular classification
Enzyme, Kinase, Protein kinase, Serine/threonine kinase, CK1 protein kinase family
01

Overview

Casein kinase 1 alpha 1 like (CSNK1A1L) is a serine/threonine protein kinase belonging to the CK1 family, involved in signal transduction, negative regulation of canonical Wnt signaling, and phosphorylation of various substrate proteins. It localizes primarily to the cytoplasm and nucleus, and its function has been implicated in the regulation of β-catenin stability, cell cycle progression, and potentially in the modulation of p53 and NF-κB signaling. CSNK1A1L is associated with multiple physiological processes and disease states, such as cancer, neurodegeneration (Alzheimer's disease), and hematologic malignancies. Although not as extensively studied as the closely related CSNK1A1 (CK1α), this kinase shares key functional, substrate, and regulatory features within the CK1 family, suggesting a potential as a drug target and biomarker in relevant contexts

Other names
Casein kinase I isoform alpha-likeCSNK1A1LCKI-alpha-likeMGC33182CK1casein kinase I alpha S-likecasein kinase 1 alpha 1 likecasein kinase 1 α 1 like
02

Mechanism of action

Ubiquitination and proteasomal degradation of the kinase (e.g., by lenalidomide); Direct kinase inhibition (e.g., by small-molecule inhibitors like D4476)

03

Biological functions

Signal transductionNegative regulation of Wnt signaling pathwayProtein phosphorylationRegulation of cell cycle progressionRegulation of β-catenin degradation
04

Disease associations

Cancer (colorectal cancer, renal cell carcinoma, liposarcoma, melanoma, prostate cancer, pancreatic cancer, leukemia, multiple myeloma)Neurodegenerative disease (Alzheimer’s Disease)Hematologic malignancies (myelodysplastic syndrome, adult T cell leukemia/lymphoma)Other (Pompe Disease, possible roles in inflammation and immune response)
05

Safety considerations

Modulation can impact multiple signaling pathways (Wnt, p53, NF-κB) with risks of immune dysregulationPotential for cytotoxicity if normal cell cycle control or protein degradation pathways are disrupted
06

Interacting drugs

Lenalidomide (induces degradation of CK1α in closely related protein CSNK1A1, with mechanistic overlap likely for CSNK1A1L)

2 more in the full profile.

07

Biomarkers

Downregulation or mutation may serve as a prognostic marker in certain cancers (e.g., colorectal cancer, myelodysplastic syndrome)Expression patterns may indicate risk or progression in neurodegeneration and hematologic disorders

Beyond the preview

Go deeper on Casein kinase 1 alpha 1 like (CSNK1A1L).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Casein kinase 1 alpha 1 like (CSNK1A1L).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call